Cover Image

To assess cardio-vascular risks in diabetes mellitus type – 2 and its correlation with non-alcoholic fatty liver disease

Nikhil Verma*, Jaswant Singh, Tarsem Pal Singh, Dr. Sapna, Praveen Garg

Abstract


DM is the most common endocrine disease of human characterized by metabolic abnormalities leading to long term complication involving heart, kidney, liver, GIT, nerves and blood vessels, thereby causing morbidity and mortality. Diabetic patients often develop cardiovascular disease and it is the main cause of the high risk of premature death in these patients. Compared with non-diabetic subjects, people with tpe-2 DM appear to have an increased risk of developing Non-alcoholic fatty liver disease and certainly have a higher risk of developing fibrosis and cirrhosis. Metabolic syndrome is a strong predictor of Non-alcoholic fatty liver disease. A total number of 100 diabetic patients were included in the study. After the detailed history, clinical examination, ultrasonography and other planned investigations, 50 patients were found to have Non-alcoholic fatty liver disease while 50 patients were without Non-alcoholic fatty liver disease. The prevalence of metabolic syndrome in diabetic patients was 59%. 70% of Non-alcoholic fatty liver disease patients were having metabolic syndrome while in patients without Non-alcoholic fatty liver disease were having 48%. Metabolic syndrome is a well- known precursor of cardiovascular disease. Recognition of their presence, early diagnosis and management of these cardiovascular risk can reduce morbidity and mortality in diabetic patient.

Keywords


Diabetes Mellitus; Non Alcoholic Fatty Liver; Metabolic Syndrome; Cardiovascular risk.

Full Text:

PDF

References


Javitt JC, Yen-Pin Chiang YP (1995) Economic Impact of Diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) Diabetes in America, 2ndedn. National Diabetes Data Group of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Marylan

American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 31:296–309

Selby JV, Ray GT, Zhang D, Colby CJ (1997) Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20:1396–1402

Geiss LS, MA, Herman WH, Smith PJ (1995) Mortality innon-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) Diabetes in America, 2nd edn. National Diabetes Data Group of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, pp 233–257

Stamler J, Vaccaro O, Neaton JD, Wenworth DW (1993) Diabetes, other risk factors, and 12-Yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes are 16:434–443

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234

Turner RC, Millns H, Neil HA et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 316:823–828

Balrajan R. Ethnic difference in mortality from IHD and CVD in England and Wales. BMJ. 1991;302:560-4

McKeigue PM, Miller GJ, Marmot MG. CHD in south Asian overseas: A review. J Clin Epidemiol. 1989;42:597-609

Parving HH, Gall MA, Scott P, et al. Prevalence and causes of albuminuria in non-insulin dependent diabetic patients. Kidney Int. 1992;41:758-62

Alvin C. Powers: Diabetes Mellitus. Harission 2008;338:2286

Deepak Amarapurkar, Prafull Kamani, et al. Prevalence of NAFLD. Hepatology 2007; 6 (3):161-163.

Masahide Hamaguchi, Takao Kojima, et al. World J Gastroentrol 2007; 13:1579-1584.

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219

Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395

Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004; 19: 368-374

Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 2003; 26: 3351-3352

Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19: 854-858

Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-1934

Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-1023

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-778.

Nicola Villanova, Simona Moscatiello, et al. Endothelial Dysfunction and Cardiovascular Risk Profile in Nonalcoholic Fatty Liver Disease. Hepatology 2005; 42:473-480.




DOI: http://dx.doi.org/10.21746/ijbio.2015.01.0018

Refbacks

  • There are currently no refbacks.




Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.